with hematological malignancies and other life-threatening conditions. Evidence on nonpersistence and nonadherence to oral medications for chronic conditions among patients following HCT is lacking. OBJECTIVES This study aims to examine patterns of oral medication use for chronic conditions following HCT in the U.S. population. METHODS Nonpersistence and nonadherence to oral medications for diabetes, hypertension, and dyslipidemia among HCT recipients were assessed in a cohort that included 1382 autologous and 650 allogeneic HCT recipients with hematological malignancies using the Truven Health MarketScan Research Database between 2009 and 2014. Recipients of HCT were compared to propensity scorematched cancer patients receiving chemotherapy without transplantation. Multivariable Cox proportional hazards models and generalized estimating equations were used to determine characteristics associated with nonpersistence and nonadherence to oral chronic medications, respectively. RESULTS Recipients of HCT had higher risks of discontinuing medication for diabetes mellitus (allogeneic HCT hazard ratio [HR] = 1.93, 95% confidence interval [CI] 1.10-3.39; autologous HCT HR = 1.49, 95% CI 1.04-2.15); hypertension (allogeneic HCT HR = 1.75, 95% CI 1.21-2.53; autologous HCT HR = 1.32, 95% CI 1.07-1.62), and dyslipidemia (allogeneic HCT HR = 2.02, 95% CI 1.39-2.93; autologous HCT, HR = 1.26, 95% CI 0.98-1.61) compared to patients treated with only chemotherapy. Lower odds of adherence to antihypertensive medications (odds ratio [OR] = 0.58, 95% CI 0.38-0.89) and to lipid-lowering medications (OR = 0.38, 95% CI 0.22-0.65) were observed in allogeneic HCT recipients compared with propensity score-matched patients who underwent chemotherapy only.
INTRODUCTION Hematopoietic cell transplantation (HCT) is an established curative option for patients
with hematological malignancies and other life-threatening conditions. Evidence on nonpersistence and nonadherence to oral medications for chronic conditions among patients following HCT is lacking. OBJECTIVES This study aims to examine patterns of oral medication use for chronic conditions following HCT in the U.S. population. METHODS Nonpersistence and nonadherence to oral medications for diabetes, hypertension, and dyslipidemia among HCT recipients were assessed in a cohort that included 1382 autologous and 650 allogeneic HCT recipients with hematological malignancies using the Truven Health MarketScan Research Database between 2009 and 2014. Recipients of HCT were compared to propensity scorematched cancer patients receiving chemotherapy without transplantation. Multivariable Cox proportional hazards models and generalized estimating equations were used to determine characteristics associated with nonpersistence and nonadherence to oral chronic medications, respectively. RESULTS Recipients of HCT had higher risks of discontinuing medication for diabetes mellitus (allo- The number of autologous transplant recipients increased to > 15,000/year, owing primarily to the trend of increased HCT for plasma cell and lymphoproliferative disorders in older patients. 1 Among these patients, 38% of allogeneic transplantations were performed in patients who were 50 years and older between 2000 and 2015, with 25% occurring in patients older than age 60 years. 2 Nonadherence is generally defined as the extent of nonconformity in terms of timing, dosage, frequency, and duration when patients take a prescribed medication, and nonpersistence refers to early self-discontinuation of a medication prescribed by health care providers. 3 A meta-analysis described that up to 41% of patients take their chronic medication for less than 80% of the days' on therapy in a year. 4 With improvements in supportive care, HCT is increasingly being offered in outpatient settings. 5, 6 The transition in the immediate post-HCT period poses risks to these patients on potential underuse of their chronic medications, especially in the fragmented U.S. health system where multiple studies indicate that the rate of adherence to oral medications decrease over time. 7 A recent systematic review indicated that nonadherence to oral medications ranged from 5.3% to 67% among patients undergoing HCT, primarily in smaller institutional cohorts or registry-based studies. 8, 9 Although evidence from these settings is real world in nature, much of the data were limited by reliance on self-reporting of medication adherence and subject to recall bias. Poor medication adherence and discontinuation of treatment may have significant clinical implications including increased risks of infection, increased health care resource utilization, disease progression, and mortality. [10] [11] [12] [13] [14] Evidence remains sparse on changes in chronic medication adherence among cancer patients undergoing HCT.
In the present study, we examine adherence and persistence to medications for hypertension, diabetes, and dyslipidemia in patients undergoing HCT given that (i) these medications are prevalent in the elderly population undergoing HCT; (ii) more HCT survivors live into their fifth decade and beyond, and increasingly become at risks of these metabolic disorders; and (iii) there is relatively abundant studies from the general population on medication utilization patterns for these conditions, providing a benchmark for chronic medication adherence and persistence in patients not receiving HCT.
Hypothesis and Objective
We hypothesized that patients undergoing HCT may have lower adherence and persistence to chronic disease treatments, specifically oral medications for diabetes, hypertension, and dyslipidemia, compared to propensity score-matched patients who underwent chemotherapy only. Numerous factors including complex medication regimens, poor care coordination, higher financial burden, depression, and the relative intensities of allogeneic versus autologous HCT may contribute to poor adherence and discontinuation of chronic medications among HCT recipients. 2, 7, 15 Our objective was to describe patterns of persistence and adherence to medications for hypertension, diabetes, and dyslipidemia following HCT and to identify contributing and modifiable factors associated with discontinuation and poor adherence after transplantation.
Methods

Data Source
We conducted a retrospective cohort study of patients with hematological malignancies who received either HCT or chemotherapy only utilizing a previously developed algorithm from a large U.S. commercial health insurance-based population between 2009 and 2014. 16 The Truven Health MarketScan Research Database is an administrative health database comprising medical and prescription drug claims for >115 million enrollees. 17 All patient data in the database were de-identified, and this study was determined to be exempt by the Institutional Review Board of the University of Illinois at Chicago.
Patient Selection and Cohort Matching
We initially identified 716,220 patients with International Classification of Diseases, Ninth Revision (ICD-9) diagnosis or procedure codes indicating hematological malignancies between January 2009 and December 2014 (Table S1 ). Adult patients aged 18-64 years were included in our study. Patients older than 65 years were excluded for this analysis given the incomplete capture of claims processed in the absence of supplemental Medicare coverage. All patients were required to have an eligible hematological malignancy diagnosis documented during the study period, in addition to at least 6 months of continuous enrollment before and 12 months continuous enrollment after index diagnosis date. Continuous enrollment is defined as absence of any gap in health insurance coverage for > 30 days from the beginning of health plan coverage. Patients in the transplantation cohorts were identified if they had at least one inpatient or two or more outpatient claims with an ICD-9 procedure code or Current Procedural Terminology (CPT) code for allogeneic HCT (ICD- Figure 1 ). Patients in the matched comparison cohort were sampled from the population of eligible hematological malignancy patients, based on diagnosis codes and prescription fill records for oral chronic medications during the 6-month baseline period prior to the date of cancer diagnosis. For each transplant cohort, allogeneic HCT and autologous HCT recipients were propensity score-matched to patients receiving treatment with chemotherapy-alone treatment without HCT. Age, gender, health plan type, region, types of diagnosis, year of diagnosis, and National Cancer Institute (NCI) comorbidity index were fit in logistic regression models for propensity to receive HCT. [19] [20] [21] [22] Per cohort, each HCT recipient was then matched to three patients receiving chemotherapy only whose predicted propensity to receive HCT were the nearest to the index transplant recipient.
The date of stem cell transplantation was defined as the index date for the transplant patients. Index dates were assigned in the chemotherapy-only cohort based on a corresponding lagged time between diagnosis and stem cell transplantation for matched HCT recipients. Pharmacy dispensing records of oral medications with an indication for diabetes, hypertension, and dyslipidemia were ascertained (Table S2) , as well as for parenteral medications used concurrently.
Study Variables
Medication discontinuation and nonadherence to oral chronic medications were the primary outcomes of interest. Patients were followed for up to 3 years following the date of transplantation (or corresponding index date). The schema for subject selection and data collection during the study period is depicted in Figure 2 .
Medication persistence and adherence as measured by treatment gaps and coverage or possession ratios, respectively, are validated as a reproducible measure using electronic administrative pharmacy claims data. 23 Medication discontinuation was defined as the presence of treatment gaps without any medication class coverage for ≥ 60 days. Patients were followed for discontinuation of the medication classes of interest until the first of 3 years after index date, disenrollment from the health plan, or the end of study period (December 2014). Medication adherence was assessed using proportion of days covered (PDC) as a time-dependent outcome measured over subsequent 6-month periods. Patients were considered adherent during each 6-month period if PDC was ≥ 0.8. The 6-monthly medication adherence to chronic condition, as measured by PDC, was assessed at baseline in addition to the observation period, divided into a maximum of six 6-month consecutive time periods from the index date. Proportion of days covered measures were adjusted using inpatient admission data by assuming 100% medication adherence during hospitalizations. 24, 25 Patient demographic information and clinical characteristics were collected and considered for inclusion as confounders in multivariable models. Multivariable models included the following time-invariant covariates of interest selected a priori: age at diagnosis; gender; NCI comorbidity index in the 6-month baseline period prior to cancer diagnosis; type of hematological malignancy; presence of the other chronic conditions of interest; and time-varying characteristics assessed each 6-month period including use of injectable diabetes medications and prevalent diagnoses of depression, nausea, emesis, diarrhea, malnutrition, and graft-versus-host disease (GVHD) among allogeneic HCT recipients. We determined patients with GVHD as having (i) treatment with immunosuppressive medications, including tacrolimus, cyclosporine, corticosteroids, mycophenolate, sirolimus, azathioprine, and others (Table S2 ) and (ii) one or more post-transplant claims with a diagnosis of GVHD (ICD-9, 279.5) during the same 6-month period.
Statistical Analysis
Descriptive statistics were used to determine differences in baseline characteristics between groups. We used v 2 and Student t tests to compare baseline clinical and demographic characteristics across treatment groups for categorical and continuous variables, respectively. The KaplanMeier method was used to assess time until medication discontinuation following the index date, and log-rank tests were used to compare the equality of survivor functions. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between HCT and medication nonpersistence were estimated using multivariable Cox proportional hazards models, as well as the associations between HCT and other clinical characteristics.
Proportion of days covered was estimated during successive 6-month periods following the index date with the value of PDC of ≥ 0.8 indicating a patient being adherent as our primary adherence outcome. We used generalized estimation equations (GEEs) to take into account withinpatient correlation over successive time periods and estimate a population-averaged effect of HCT on medication adherence as adjusted odds ratio (OR) and robust 95% CI. These repeated measures were estimated over the observational period with exchangeable working correlation matrices and a binary distribution. 26 The advantage of the GEE method applied here was to estimate the population-averaged differences, robust to possible misspecification of the correlation structure. 27 Differences were considered statistically significant at p<0.05.
Sensitivity analyses were conducted using PDC thresholds of 0.70 and 0.90 for medication adherence. We also varied the allowed period for treatment gaps between 30 and 90 days in evaluating medication persistence. Results from these analyses were not substantively different and we present here our main findings only.
Data management and statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and open-source software R 3.4.1 (geepack package, https://CRAN.R-project.org).
Results
Baseline Characteristics
A total of 650 eligible allogeneic HCT recipients and 1382 autologous HCT recipients were included in the final analytic cohort. In addition, 23,349 patients who received chemotherapyalone treatment were identified as a reference group. Descriptive characteristics of these patients at baseline are reported in Table 1 . Median age was 54, 56, and 54 years for allogeneic HCT, autologous HCT, and chemotherapy-alone cohorts, respectively. Most of the allogeneic HCT recipients had diagnoses for acute leukemia (70.5%), whereas the majority of autologous HCT recipients had multiple myeloma (MM) (72.0%) and non-Hodgkin's lymphoma (NHL) (23.2%). Allogeneic and autologous HCT recipients were slightly less likely to have diabetes compared to chemotherapy-alone cohort, 12.0%, 10.9%, and 14.2%, respectively (p=0.0011). Hypertension was more common in autologous HCT recipients (35.2%) and was slightly lower among patients treated with chemotherapy only (30.7%) and allogeneic HCT recipients (27.5%) (p=0.0003). No differences in the prevalence of dyslipidemias were observed between treatment groups.
Medication Discontinuation
Persistence in each medication class following HCT differed by type of chronic condition and stratified by allogeneic or autologous transplantation. Kaplan-Meier survival curves for treatment discontinuation are shown in Figure 3 . During the follow-up period, 74.1% of the allogeneic HCT recipients and 68.3% of the autologous HCT recipients experienced treatment gaps for oral diabetes medications compared to 54.3% in chemotherapy-only group at 12 months after transplantation. A total of 67.1% of the allogeneic HCT recipients and 60.0% of the autologous HCT recipients had treatment gaps of oral antihypertensive medications at 12 months compared to 47.8% in the chemotherapy-only group. For patients with dyslipidemias, 79.0% of the allogeneic HCT recipients and 63.1% of the autologous HCT recipients experienced treatment gaps ALL = acute lymphoblastic leukemia; AMI = acute myocardial infarction; ANLL = acute non-lymphoblastic leukemia; CDHP = consumerdirected health plan; COPD = chronic obstructive pulmonary disease; EPO/PPO = exclusive provider organization/preferred provider organization; HCT = hematopoietic cell transplantation; HD = Hodgkin disease; HDHP = high-deductible health plan; HMO = health maintenance organization; IQR = interquartile range; MDS = myelodysplastic syndromes; MM = multiple myeloma; MPNs = myeloproliferative neoplasms; NCI = National Cancer Institute; NHL = non-Hodgkin lymphoma; POS = point of service; SD = standard deviation.
of oral lipid-lowering medications at 12 months compared to 53.2% in chemotherapy-only group. Significant differences in medication persistence were observed in the allogeneic HCT cohort compared with the chemotherapy-alone cohort for antihypertensive medications (p=0.0015) and lipidlowering medications (p<0.0001). For the autologous HCT cohort, significant differences in persistence were observed for diabetes medications (p=0.027) and lipid-lowering medications (p=0.02).
Medication Adherence
In Figure 4 , we illustrate a substantial proportion of patients with suboptimal adherence to medications for diabetes, hypertension, and dyslipidemias at baseline (6 mo prior to transplant or matched index lag time period). At baseline, 48.2% of allogeneic HCT recipients and 49.2% of autologous HCT recipients were adherent to diabetes medications. For hypertensive medications, 44.3% of the allogeneic HCT recipients and 44% autologous HCT recipients were adherent to oral antihypertensives at baseline. For lipid-lowering medications, 30.7% of allogeneic HCT recipients and 36.8% of autologous HCT recipients were adherent at baseline. Significant differences in medication adherence were observed in allogeneic HCT cohort (p<0.001) and autologous HCT cohort (p=0.017) for lipidlowering medications using GEE models, compared with the chemotherapy-alone cohort.
Characteristics Associated with Medication Persistence
In multivariable Cox proportional hazard models, allogeneic HCT patients had greater risk of discontinuation of oral medications to treat diabetes (HR = 1.93, 95% CI 1.10-3.39), hypertension (HR = 1.75, 95% CI 1.21-2.53), and dyslipidemias (HR = 2.02, 95% CI 1.39-2.93) compared to the matched chemotherapy-only cohort. Autologous HCT was also associated with discontinuation of diabetes medications (HR = 1.49, 95% CI 1.04-2.15) and hypertensive medications (HR = 1.32, 95% CI 1.07-1.62). Patients receiving autologous HCT also demonstrated an elevated but nonsignificant risk of discontinuation for lipid-lowering medications (HR = 1.26, 95% CI 0.98-1.61) ( Figure 5 ).
Depression following transplant was negatively associated with persistence to diabetes medications in autologous HCT recipients during the follow-up (HR = 2.10, 95% CI 1.04-4.24), and nausea, emesis, and diarrhea adversely affected persistence for lipid-lowering medications in the autologous HCT cohort (HR = 1.70, 95% CI 1.13-2.54) (Table S3 ).
Factors Associated with Medication Nonadherence
In GEE models determining characteristics associated with nonadherence, allogeneic HCT recipients were less likely to be adherent to antihypertensive medications (OR = 0.58, 95% CI 0.38-0.89) and lipid-lowering medications (OR = 0.38, 95% CI 0.22-0.65). The autologous HCT recipients were less likely to be adherent to lipid-lowering medications (OR = 0.73, 95% CI 0.53-0.995).
In multivariable GEE models, younger age was associated with suboptimal adherence to diabetes and hypertensive medications. Malnutrition was associated with nonadherence to hypertensive medications in the autologous HCT cohort (OR = 0.41, 95% CI 0.25-0.66), as well as for lipid-lowering medications in both allogeneic and autologous HCT cohorts, (OR = 0.23, 95% CI 0.07-0.76, and OR = 0.51, 95% CI 0.27-0.97, respectively) ( Figure 6 , Table S4 ).
Discussion
To our knowledge, this is the first study using a large, nationally representative administrative health claims database to provide real-world evidence regarding chronic medication persistence and adherence in HCT recipients with diabetes, hypertension, and dyslipidemia. Our findings indicate higher rates of chronic medication discontinuation and nonadherence occurring within the 12-month post-HCT period in both autologous and allogeneic HCT recipients after controlling for baseline demographic characteristics, comorbidities, and common diagnoses.
We identified that depression was independently associated with discontinuation of diabetes medications among autologous HCT patients. These findings are consistent with other evidence indicating depression as a risk factor for medication nonadherence among patients with type 2 diabetes mellitus. 28, 29 Patients with depression are more likely to experience medication nonadherence and less likely to receive monitoring with hemoglobin A 1c tests compared to patients without depression. 30 This is particularly relevant to patients undergoing HCT since depression is one of the most prevalent comorbid conditions among cancer patients, affecting between 17% and 48% of adult patients. 31, 32 Increased medication nonadherence associated with depression deserves clinical attention as depression is also related to greater risk of mortality among patients after HCT. 28, 29 Screening for symptoms of major depressive disorder should be part of the routine practice in pretransplant assessment. 33 If confirmed, psychological and pharmacological interventions for depression may be helpful throughout peri-transplant and post transplant care.
Gastrointestinal symptoms including nausea, emesis, and diarrhea were related to discontinuation of medications to treat dyslipidemias. We also found that malnutrition was a key factor associated with nonadherence to antihypertensive and lipid-lowering medications. In the short term, discontinuation or holding of these treatments may be warranted given changing diet and other clinical factors associated with HCT. Due to limitations of our data, we are unable to evaluate the causes of gastrointestinal symptoms or malnutrition. However, viral, bacterial, and fungal infections, as well as toxicity of HCT to the digestive tract are common following HCT. [34] [35] [36] [37] [38] In addition, gastrointestinal GVHD would also play an important role on the patient's nutritional status, which may affect oral medication adherence. 39 Interventions including parenteral and/or enteral nutrition to alleviate gastrointestinal symptoms may also be important to improving tolerance to chronic disease medications after transplant. 40 We found that a large proportion of HCT patients with diabetes discontinued their oral hypoglycemic medications or had suboptimal adherence to diabetes medication compared to baseline. Given the progression of therapy for advancing diabetes, the reason for observed poor adherence was possibly related to use of parenteral moderate-or long-acting insulin therapy. Indeed, we assessed that the proportion of patients who received insulin at baseline, between malignancy diagnosis and transplant, and during the 6-month period post transplant was 21%, 40%, and 30% for autologous HCT; and 26%, 56%, and 67% for allogeneic HCT, respectively. We accounted for these changes in management of glycemic control by defining insulin use as a time-dependent variable in our GEE models assessing oral diabetes medication adherence. Due to limited information from pharmacy dispensing records on dosing and days' supply of insulin products, we were not able to estimate comparable insulin adherence; nevertheless, these were either adjusted for directly or by stratification in multivariable models.
Implications for Practice
These findings have important policy, research, and clinical implications. The 3-year survival rate after HCT ranges from 60% to 84%, and the 5-year survival rate is >50% for most indications. 1 Thus, not only do a large number of older HCT recipients have pre-existing chronic conditions, but many younger HCT recipients are likely to survive into their elderly years and could develop metabolic disorders.
After successful HCT, relapse-free patients are likely to be transferred to their primary health care providers to resume management of chronic conditions, including monitoring of glycemic control, blood pressure, and lipid levels. Although there are few publications on pharmacotherapy in the post-HCT population, we believe that this study helps to elucidate the risk factors and barriers to adherent chronic medication treatment. Our study demonstrated that younger patients and patients with poor adherence to chronic medications at baseline were more likely to experience medication discontinuation and nonadherence after transplant. Therefore, evaluation of patients' baseline medication adherence using pill counting, electronic dispensing records, or self-reported medication adherence measures should be considered as routine practice in the pretransplantation assessment. A comprehensive evaluation of adherence to chronic disease medications in patients receiving HCT will enable clinicians to identify patients at risk of nonadherence to both cancer-and noncancer-directed therapies. Evaluation of specific clinical factors, such as depression, malnutrition, and gastrointestinal symptoms, may also be warranted to improve medication adherence and persistence, giving providers the opportunities to design tailored clinical management strategies of HCT care.
Strengths and Limitations
Although to our knowledge this is the largest study of HCT patients describing adherence and persistence to medications for diabetes, hypertension, and dyslipidemias, several important limitations should be considered when interpreting our findings. First, adherence to medication is a complex behavior and we were unable to determine the reasons for medication discontinuation and nonadherence. However, we conducted multiple sensitivity analyses and determined our results to be robust to varying assumptions of adherence and persistence. Second, we were unable to differentiate temporal withholding of medications ordered by physicians secondary to drug-drug interactions and medication discontinuation due to other reasons. The exact reasons for medication discontinuation or suboptimal adherence rates to chronic Figure 6 . Forest plot for associations with adherence across three conditions using multivariate GEE models. (Multivariable analyses adjusted for age, gender, CCI, parenteral antidiabetic medication use, and concomitant chronic conditions.) CCI = Charlson Comorbidity Index; CI = confidence interval; GVHD = graft-versus-host disease; HCT = hematopoietic cell transplantation; NCI = National Cancer Institute; OR = odds ratio. medications could not be ascertained, as well as other measures of clinical control such as measured blood pressure, glycated hemoglobin, or lipid values over time, which are subject to change after initiation of immunosuppressant therapy, such as cyclosporine and sirolimus. Third, we relied on diagnosis codes and procedure codes from the administrative database to determine clinical characteristics, which could be subject to possible misclassification. However, we required eligible patients to have diagnosis and procedure codes in addition to prescription refill records to select patients included in our chronic disease cohorts. As in any observational, nonrandomized study, residual confounding by unmeasured covariates is possible. Lastly, our study was limited to patients under 65 years of age, and these findings may not be entirely representative of older HCT recipients.
Conclusions
Patients with chronic metabolic conditions undergoing HCT for underlying hematological malignancies experienced significant discontinuation and nonadherence compared to patients treated only with chemotherapy. We also identified several clinical characteristics associated with medication discontinuation and adherence. Adherence to medication for chronic conditions and depressive symptoms should be assessed at baseline to identity patients at higher risks of medication discontinuation, and monitoring of medication adherence should be considered among younger transplant recipients with chronic comorbid conditions. Further research incorporating electronic medical records is needed to confirm our findings, and efforts should be made differentiating patient-and provider-related factors associated with poor medication adherence and persistence. As HCT is increasingly performed among older patients and those with pre-existing comorbid conditions, education to improve quality chronic condition care and transition to non-intensive care settings would be well motivated.
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